Agilon Health (NYSE:AGL) Announces Quarterly Earnings Results

Agilon Health (NYSE:AGL) released its quarterly earnings data on Wednesday. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.92, FiscalAI reports. Agilon Health had a negative return on equity of 146.03% and a negative net margin of 6.09%.The company had revenue of $1.49 billion during the quarter, compared to analysts’ expectations of $1.45 billion.

Agilon Health Stock Performance

Shares of NYSE AGL traded up $11.77 during trading hours on Wednesday, reaching $106.55. 1,112,918 shares of the stock were exchanged, compared to its average volume of 354,822. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -4.94 and a beta of 3.01. The stock’s fifty day simple moving average is $106.46 and its 200 day simple moving average is $54.68. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.04 and a current ratio of 1.04. Agilon Health has a 52 week low of $7.48 and a 52 week high of $133.04.

Analyst Ratings Changes

AGL has been the topic of a number of recent analyst reports. Jefferies Financial Group raised Agilon Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $27.50 to $48.00 in a report on Thursday, May 7th. Weiss Ratings cut shares of Agilon Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 27th. Citigroup downgraded shares of Agilon Health from a “neutral” rating to a “sell” rating and upped their price objective for the company from $80.00 to $105.00 in a report on Thursday, July 23rd. Wells Fargo & Company reissued an “overweight” rating and issued a $141.00 price objective (up from $72.00) on shares of Agilon Health in a research report on Monday, July 13th. Finally, TD Cowen restated a “hold” rating and set a $55.00 target price (up from $17.00) on shares of Agilon Health in a research note on Monday, May 11th. Five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $66.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Invesco Ltd. lifted its holdings in shares of Agilon Health by 30.7% during the fourth quarter. Invesco Ltd. now owns 1,004,266 shares of the company’s stock worth $692,000 after buying an additional 235,951 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Agilon Health in the fourth quarter valued at about $86,000. Numerai GP LLC increased its position in Agilon Health by 207.3% during the fourth quarter. Numerai GP LLC now owns 1,228,071 shares of the company’s stock worth $846,000 after acquiring an additional 828,472 shares during the period. Odyssean LLC bought a new position in Agilon Health during the fourth quarter worth about $96,000. Finally, Inspire Investing LLC raised its stake in Agilon Health by 62.7% in the 4th quarter. Inspire Investing LLC now owns 695,929 shares of the company’s stock worth $479,000 after purchasing an additional 268,218 shares in the last quarter.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.